ANTI-ERYPTOTIC POTENTIAL OF SELENIUM AGAINST GENTAMICIN-INDUCED ERYPTOSIS

Gentamicin, an aminoglycoside, is used to treat serious infections such as blood infections (septicemia) and brain and spinal cord infections. Recent years have shown an increase in antibiotic use, which can be associated with side effects like eryptosis, a process mainly induced by oxidative stress, ceramide production, and energy depletion, which can lead to anemia. Eryptosis, quite similar to apoptosis, is defined by cell shrinkage, membrane blebbing, and membrane phospholipid scrambling with phosphatidylserine exposure at the cell surface. The core purpose of this research was to examine the eryptotic effect of gentamicin through the oxidative stress pathway and study the anti-eryptotic potential of selenium against gentamicin-induced eryptosis. In this study, erythrocytes were treated with therapeutical doses (9-18μM) of gentamicin and selenium for 48 hours according to experimental requirements. To assess the cytotoxicity of gentamicin hemolysis% was estimated, the oxidative potential of gentamicin and the anti-oxidative potential of selenium was confirmed by investigating the levels of glutathione peroxidase, superoxide dismutase and catalase, to confirm their eryptotic role mean cell volume(MCV) was measured, role of Ca+2 in eryptosis was confirmed by using a calcium-channel blocker, amlodipine. Results illustrate that an increase in gentamicin concentration directly affects hemolysis%, gentamicin treated cells showed low levels of enzyme activity while gentamicin+ selenium-treated cells showed better activity of antioxidants, less than normal MCV was observed in gentamicin-treated cells which is a direct indication that cell is going through eryptosis, calcium channel blocker showed the involvement of Ca2+ in eryptosis.